New biological research framework for Alzheimer's seeks to spur discovery

April 10, 2018, National Institutes of Health
This table shows column of the eight biomarker profiles (left) and corresponding categories (right) outlined in the framework that could be used to group research participants. The biomarker profiles can be sorted into three broader categories: Normal Alzheimer's biomarkers, Alzheimer's continuum and non-Alzheimer's pathologic change. Credit: NIA-AA Research Framework

The research community now has a new framework toward developing a biologically-based definition of Alzheimer's disease. This proposed "biological construct" is based on measurable changes in the brain and is expected to facilitate better understanding of the disease process and the sequence of events that lead to cognitive impairment and dementia. With this construct, researchers can study Alzheimer's, from its earliest biological underpinnings to outward signs of memory loss and other clinical symptoms, which could result in a more precise and faster approach to testing drug and other interventions.

The National Institute on Aging (NIA), part of the National Institutes of Health, and the Alzheimer's Association (AA) convened the effort, which as the "NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease," appears in the April 10, 2018 edition of Alzheimer's & Dementia: The Journal of the Alzheimer's Association. Drafts were presented at several scientific meetings and offered online, where the committee developing the gathered comments and ideas which informed the final published document. The framework, as it undergoes testing and as new knowledge becomes available, will be updated in the future.

The framework will apply to clinical trials and can be used for observational and natural history studies as well, its authors noted. They envision that this common language approach will unify how different stages of the disease are measured so that studies can be easily compared and presented more clearly to the medical field and public.

"In the context of continuing evolution of Alzheimer's research and technologies, the proposed research framework is a logical next step to help the scientific community advance in the fight against Alzheimer's," said NIA Director Richard J. Hodes, M.D. "The more accurately we can characterize the specific disease process pathologically defined as Alzheimer's disease, the better our chances of intervening at any point in this continuum, from preventing Alzheimer's to delaying progression,"

Evolution in thinking

This framework reflects the latest thinking in how Alzheimer's disease begins perhaps decades before outward signs of and decline may appear in an individual. In 2011, NIA-AA began to recognize this with the creation of separate sets of diagnostic guidelines that incorporated recognition of a preclinical stage of Alzheimer's and the need to develop interventions as early in the process as possible. The research framework offered today builds from the 2011 idea of three stages—pre-clinical, mild and dementia—to a biomarker-based disease continuum.

The NIA-AA research framework authors, which included 20 academic, advocacy, government and industry experts, noted that the distinction between clinical symptoms and measurable changes in the brain has blurred. The new research framework focuses on biomarkers grouped into different pathologic processes of Alzheimer's which can be measured in living people with imaging technology and analysis of cerebral spinal fluid samples. It also incorporates measures of severity using biomarkers and a grading system for cognitive impairment.

"We have to focus on biological or physical targets to zero in on potential treatments for Alzheimer's," explained Eliezer Masliah, M.D., director of the Division of Neuroscience at the NIA. "By shifting the discussion to neuropathologic changes detected in biomarkers to define Alzheimer's, as we look at symptoms and the range of influences on development of Alzheimer's, I think we have a better shot at finding therapies, and sooner."

In an accompanying editorial, Masliah and NIA colleagues, including Dr. Hodes, highlighted both the promise and limitations of the biological approach. They noted that better operational definitions of Alzheimer's are needed to help better understand its natural history and heterogeneity, including prevalence of mimicking conditions. They also emphasized that the research framework needs to be extensively tested in diverse populations and with more sensitive biomarkers.

Batching and matching biomarkers

The NIA-AA research framework proposes three general groups of biomarkers—beta-amyloid, tau and neurodegeneration or neuronal injury—and leaves room for other and future biomarkers. Beta-amyloid is a naturally occurring protein that clumps to form plaques in the brain. Tau, another protein, accumulates abnormally forming neurofibrillary tangles which block communication between neurons. Neurodegeneration or neuronal injury may result from many causes, such as aging or trauma, and not necessarily Alzheimer's disease.

Researchers can use measures from a study participant and identify beta-amyloid (A), tau (T) or neurodegeneration or neuronal injury (N) to characterize that person's combination of biomarkers in one of eight profiles. For example, if a person has a positive beta-amyloid (A+) biomarker but no tau (T-), he or she would be categorized as having "Alzheimer's pathologic change." Only those with both A and T biomarkers would be considered to have Alzheimer's disease, along a continuum. The N biomarker group provides important pathologic staging information about factors often associated with Alzheimer's development or worsening of symptoms.

Framework for certain research only

The authors emphasized that the NIA-AA research framework is neither a diagnostic criteria nor guideline for clinicians. It is intended for research purposes, requiring further testing before it could be considered for general clinical practice, they noted.

They also stressed that the biological approach to Alzheimer's is not meant to supplant other measures, such as neuropsychological tests, to study important aspects of the disease such as its cognitive outcomes. In some cases, the article pointed out, biomarkers may not be available or requiring them would be counterproductive for particular types of research.

The authors acknowledge that the research framework may seem complex, but stress that it is flexible and may be employed to answer many research questions, such as how cognitive outcomes differ among various profiles, and what the influence of age is on those relationships.

In its commentary the NIA leadership developed a table to help explain how the proposed framework might be used and where it might not apply:

The research framework is...

  • A testable hypothesis
  • An approach that facilitates standardized research reporting
  • A common language and a reference point for researchers for longitudinal studies and clinical trials
  • A welcome for other approaches
  • A welcome for other indicators of Alzheimer's and comorbidities

The research framework is NOT...

  • A requirement for NIH grant submission
  • A statement about Alzheimer's pathogenesis or etiology
  • An NIA policy, guideline or criterion for papers or grants
  • A disease definition for standard medical use
  • A fixed notion of Alzheimer's

Explore further: Alzheimer's proteins in ICU survivors

More information: Jack CR et al. NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease. Alzheimers Dement. 2018 Apr 10. DOI: 10.1016/j.jalz.2018.02.018

Silverberg N et al. NIA commentary on the NIA-AA research framework: Towards a biological definition of Alzheimer's disease. Alzheimers Dement. 2018 Apr 10. DOI: 10.1016/j.jalz.2018.03.004

Related Stories

Alzheimer's proteins in ICU survivors

March 29, 2018
While modern medicine has increased the number of people who survive a stay in the Intensive Care Unit (ICU), survivors have a high risk of developing problems with thinking and memory, a phenomenon called cognitive impairment.

New forecast shows 6 million with Alzheimer's disease, cognitive impairment

December 8, 2017
Using new methodology, scientists calculate that approximately 6 million American adults have Alzheimer's disease or mild cognitive impairment, which can sometimes be a precursor to the disease. The estimate, funded by the ...

Population of Americans with Alzheimer's will more than double by 2060, study shows

December 7, 2017
About 15 million Americans will have either Alzheimer's dementia or mild cognitive impairment by 2060, up from approximately 6.08 million this year, according to a new study by researchers at the UCLA Fielding School of Public ...

Alzheimer's drug targeting soluble amyloid falls short in a large clinical trial

January 25, 2018
A paper published today in the New England Journal of Medicine reports that solanezumab, a monoclonal antibody-based treatment for Alzheimer's disease developed by Eli Lilly that targets amyloid plaques, did not significantly ...

Single dual time-point PET scan identifies dual Alzheimer's biomarkers

June 14, 2017
More people die of Alzheimer's disease than prostate and breast cancer combined. Identifying the disease before major symptoms arise is critical to preserving brain function and helping patients maintain quality of life. ...

Detecting Alzheimer's disease before symptoms emerge

May 31, 2017
Long before symptoms of Alzheimer's disease become apparent to patients and their families, biological changes are occurring within the brain. Amyloid plaques, which are clusters of protein fragments, along with tangles of ...

Recommended for you

Pregnancy history may be tied to Alzheimer's disease

July 18, 2018
A woman's history of pregnancy may affect her risk of Alzheimer's disease decades later, according to a study published in the July 18, 2018, online issue of Neurology, the medical journal of the American Academy of Neurology. ...

Molecular tracer, seen with PET scan, shows concentrations of abnormal proteins

July 17, 2018
In a small study of military personnel who had suffered head trauma and had reported memory and mood problems, UCLA researchers found brain changes similar to those seen in retired football players with suspected chronic ...

Yale-developed test for Alzheimer's disease directly measures synaptic loss

July 16, 2018
Yale researchers have tested a new method for directly measuring synaptic loss in individuals with Alzheimer's disease. The method, which uses PET imaging technology to scan for a specific protein in the brain linked to synapses, ...

New study highlights Alzheimer's herpes link, experts say

July 12, 2018
A new commentary by scientists at the Universities of Manchester and Edinburgh on a study by Taiwanese epidemiologists supports the viability of a potential way to reduce the risk of Alzheimer's disease.

Practice imperfect—repeated cognitive testing can obscure early signs of dementia

July 12, 2018
Alzheimer's disease (AD) is a progressive, neurodegenerative condition that often begins with mild cognitive impairment or MCI, making early and repeated assessments of cognitive change crucial to diagnosis and treatment.

The 'Big Bang' of Alzheimer's: Scientists ID genesis of disease, focus efforts on shape-shifting tau

July 10, 2018
Scientists have discovered a "Big Bang" of Alzheimer's disease – the precise point at which a healthy protein becomes toxic but has not yet formed deadly tangles in the brain.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.